Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial Models Shifting As Pharma Mulls Digital-First Launches

Executive Summary

Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.

Novartis Oncology Head Discusses Cancer Care Challenge With COVID-19

Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.

Novartis Tabrecta Is First Treatment For NSCLC With METex14 Mutation

The US FDA granted an accelerated approval for the lung cancer treatment targeting a mutation found in only about 4,000-5,000 NSCLC patients in the US each year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel